Stockscreener 앱 받기
2.29
1.72%
-0.04
시간 외 거래:
2.66
0.37
+16.16%
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GT Biopharma Appoints Michael Breen as New CEO - TipRanks
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Xeris Biopharma Holdings Inc (XERS) stock analysis: A simple moving average approach - uspostnews.com
GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Nanobodies Market Growth, Opportunities and Future Scope 2025-2032 | Merck KGaA, Sanofi, AlpalifeB Inc - newstrail.com
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - MSN
GT Biopharma Issues Warrant to Cytovance for Services Rendered - Investing.com Australia
GT Biopharma Issues Warrant to Cytovance for Services Rendered By Investing.com - Investing.com Canada
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Yahoo Finance
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
North American Morning Briefing : Stock Futures -2- - MarketScreener
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - MarketBeat
The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire
Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan
GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire
Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World
Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire
GT Biopharma Announces Exercise of Warrants - GlobeNewswire
"Signal Advance, Inc. (OTC: SIGL) Achieves Technology - openPR
GT Biopharma announces warrant exercise, plans new offering - Investing.com India
GT Biopharma announces warrant exercise, plans new offering By Investing.com - Investing.com South Africa
GTBPGt Biopharma Inc Latest Stock News & Market Updates - StockTitan
Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn
Artificial Intelligence (AI) News Live Feed - StockTitan
GT Biopharma withdraws SEC registration statement - Investing.com India
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? - StockTitan
GT Biopharma, Inc. SEC 10-K Report - TradingView
This New Nasdaq Biotech Could Revolutionize Emergency Cardiac CareHere's Why - StockTitan
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1% - Defense World
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
0.39%
3.66%
자본화:
|
볼륨(24시간):